Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis
- Abstract
- BACKGROUND/AIMS: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. METHODS: In total, 143 consecutive patients with unresectable HCC were treated with sorafenib. Among these patients, 30 patients with advanced HCC and PVTT (Vp3 or 4) were treated with sorafenib monotherapy. RESULTS: All patients had a performance status of 1 to 2 (Eastern Cooperative Oncology Group 1/2, 20/10) and Child-Pugh class A or B (A/B, 17/13). Eleven patients had modified Union for International Cancer Control stage IVA tumors, whereas 19 had stage IVB tumors. All patients had PVTT (Vp3, 6; Vp4, 24). Following sorafenib monotherapy, three patients (10.0%) had a partial response with PVTT revascularization, and nine (30.0%) had stable disease, with a disease control rate of 33.3%. The median overall survival was 3.1 months (95% confidence interval [CI], 2.70 to 3.50), and the median progression-free survival was 2.0 months (95% CI, 1.96 to 2.05). Fatigue and hand-foot skin reactions were the most troublesome side effects. CONCLUSIONS: A limited proportion of patients with advanced HCC and PVTT exhibited a remarkable outcome after sorafenib monotherapy, although the treatment results in this type of patient is extremely poor. Further studies to predict good responders to personalized therapy are warranted.
- All Author(s)
- S. W. Jeong
; J. Y. Jang
; K. Y. Shim
; S. H. Lee
; S. G. Kim
; S. W. Cha
; Y. S. Kim
; Y. D. Cho
; H. S. Kim
; B. S. Kim
; K. H. Kim
; J. H. Kim
- Issued Date
- 2013
- Type
- Article
- Keyword
- Carcinoma; hepatocellular; Portal vein; Thrombosis; Sorafenib
- Publisher
- 대한소화기학회
- ISSN
- 1976-2283
- Citation Title
- Gut and Liver
- Citation Volume
- 7
- Citation Number
- 6
- Citation Start Page
- 696
- Citation End Page
- 703
- Language(ISO)
- eng
- DOI
- 10.5009/gnl.2013.7.6.696
- URI
- http://schca-ir.schmc.ac.kr/handle/2022.oak/2979
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.